Product Candidates
New feasibility collaborations initiated in 2003: (e.g., oral form of anthrax antigen)
Conducting proof-of-concept studies for existing and potential feasibility agreements
- In parallel continue to identify key therapeutic markets that could benefit with an oral delivery option
Licensing discussions ongoing related to pre-existing feasibility programs
Feasibility: New Applications of the eligen™Technology